Prophylactic senolytic treatment in aged mice reduces seizure severity and improves survival from Status Epilepticus

Aging Cell. 2024 Sep;23(9):e14239. doi: 10.1111/acel.14239. Epub 2024 Jun 20.

Abstract

Increased vulnerability to seizures in aging has been well documented both clinically and in various models of aging in epilepsy. Seizures can exacerbate cognitive decline that is already prominent in aging. Senescent cells are thought to contribute to cognitive impairment in aging and clearing senescent cells with senolytic drugs improves cognitive function in animal models. It remains unclear whether senescent cells render the aged brain vulnerable to seizures. Here, we demonstrate that prophylactic senolytic treatment with Dasatinib and Quercetin (D&Q) reduced both seizure severity and mortality in aged C57BL/6J mice. We subjected the D&Q and VEH-treated aged mice to spatial memory testing before and after an acute seizure insult, Status Epilepticus [SE], which leads to epilepsy development. We found that senolytic therapy improved spatial memory before injury, however, spatial memory was not rescued after SE. Senescence-related proteins p16 and senescence-associated β-galactosidase were reduced in D&Q-treated aged mice. Our findings indicate that senescent cells increase seizure susceptibility in aging. Thus, prophylactically targeting senescent cells may prevent age-related seizure vulnerability.

Keywords: Status Epilepticus; Dasatinib; aging; hippocampus; pilocarpine; quercetin; seizures; senolytic.

MeSH terms

  • Aging
  • Animals
  • Cellular Senescence / drug effects
  • Dasatinib / pharmacology
  • Dasatinib / therapeutic use
  • Male
  • Mice
  • Mice, Inbred C57BL*
  • Quercetin / pharmacology
  • Quercetin / therapeutic use
  • Seizures* / drug therapy
  • Senotherapeutics / pharmacology
  • Senotherapeutics / therapeutic use
  • Status Epilepticus* / drug therapy

Substances

  • Senotherapeutics
  • Dasatinib
  • Quercetin